Gilead Sciences CEO Daniel O’Day told CNBC on Monday that the company is continuing to study new ways to use its coronavirus treatment remdesivir on patients, including potentially outside of the hospital all together.  “We’re not finished with remdesivir,” O’Day said on “Squawk Box,” one day after the biopharmaceutical company announced a $21 billion […]